CorMedix, Inc. (CRMD)
8.465
+0.08
(+1.01%)
USD |
NASDAQ |
Sep 02, 13:18
CorMedix Research and Development Expense (TTM) : 27.59M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.59M |
| March 31, 2026 | 23.35M |
| December 31, 2025 | 19.33M |
| September 30, 2025 | 12.46M |
| June 30, 2025 | 8.089M |
| March 31, 2025 | 6.297M |
| December 31, 2024 | 3.942M |
| September 30, 2024 | 4.504M |
| June 30, 2024 | 6.441M |
| March 31, 2024 | 10.59M |
| December 31, 2023 | 13.16M |
| September 30, 2023 | 13.71M |
| June 30, 2023 | 13.38M |
| March 31, 2023 | 11.80M |
| December 31, 2022 | 10.68M |
| September 30, 2022 | 11.07M |
| June 30, 2022 | 13.47M |
| March 31, 2022 | 12.78M |
| December 31, 2021 | 13.13M |
| September 30, 2021 | 12.19M |
| June 30, 2021 | 10.38M |
| March 31, 2021 | 13.54M |
| December 31, 2020 | 13.38M |
| September 30, 2020 | 13.76M |
| June 30, 2020 | 13.36M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.65M |
| December 31, 2019 | 11.05M |
| September 30, 2019 | 4.029M |
| June 30, 2019 | 9.797M |
| March 31, 2019 | 13.42M |
| December 31, 2018 | 18.82M |
| September 30, 2018 | 31.63M |
| June 30, 2018 | 29.35M |
| March 31, 2018 | 27.84M |
| December 31, 2017 | 24.49M |
| September 30, 2017 | 20.06M |
| June 30, 2017 | 20.89M |
| March 31, 2017 | 18.57M |
| December 31, 2016 | 15.74M |
| September 30, 2016 | 13.19M |
| June 30, 2016 | 8.112M |
| March 31, 2016 | 7.137M |
| December 31, 2015 | 6.282M |
| September 30, 2015 | 5.298M |
| June 30, 2015 | 3.826M |
| March 31, 2015 | 2.200M |
| December 31, 2014 | 1.319M |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Innoviva, Inc. | 28.66M |
| Zevra Therapeutics, Inc. | 14.83M |
| Filana Therapeutics, Inc. | 15.66M |
| Eloxx Pharmaceuticals, Inc. | 6.647M |
| Cannabis Global, Inc. | -- |